GlassScriptPhysician profile
Zhou Zhang
NPI 1326465451
$1,073.40
in general payments reported to CMS, 2019-2025
13 companies · $320 in 2025
The $320 reported for 2025 was more than what 89% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $171 · 2023: $236 · 2024: $134 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $269.49 | 2021-2024 | Veklury |
| Astrazeneca Pharmaceuticals LP | $173.08 | 2022-2023 | Andexxa |
| Stryker Corporation | $139.19 | 2021-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $137.98 | 2023-2025 | Cleviprex |
| Csl Behring | $123.14 | 2025 | Kcentra |
| Abbvie INC. | $64.58 | 2023-2025 | Dalvance |
| Janssen Pharmaceuticals, INC | $64.51 | 2023-2024 | Xarelto |
| Inari Medical, INC. | $23.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bioxcel Therapeutics, INC. | $18.16 | 2023 | Igalmi |
| Melinta Therapeutics, LLC | $15.60 | 2022 | |
| Oyster Point Pharma, INC. | $14.94 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.42 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhou Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.